Amarin asks Federal Circuit Court to direct US ITC to investigate its complaint that some omega-3 ingredients are unapproved drugs. Company questions FDA's request for policy deference given resource constraints and says Supreme Court rulings show compliance with FDA regulations in cosmetic and food labeling does not preclude litigation alleging the information renders a product an unapproved drug or represents false advertising.
Amarin Corp. PLC continues to wage its battle to force the International Trade Commission, or perhaps FDA, to decide explicitly whether some products marketed as dietary supplements unfairly compete with its ethyl-ester eicosapentaenoic acid omega-3 drug,
Amarin had asked ITC to investigate its complaint that the imported supplement products may violate fair trade rules. ITC recently...